



6 May 2010  
EMA/HMPC/142986/2009  
Committee on Herbal Medicinal Products (HMPC)

**This document was valid from 6 May 2010 until September 2017. It is now superseded by a [new version](#) adopted by the HMPC on 19 September 2017 and published on the EMA website.**

## Community herbal monograph on *Ribes nigrum* L., folium

Final

Discussion in Working Party on Community monographs and Community list (MLWP)	March 2009 May 2009 July 2009
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	16 July 2009
End of consultation (deadline for comments). Comments should be provided using this <a href="#">template</a> to <a href="mailto:hmpc.secretariat@ema.europa.eu">hmpc.secretariat@ema.europa.eu</a>	15 December 2009
Rediscussion in Working Party on Community monographs and Community list (MLWP)	4 May 2010
Adoption by Committee on Herbal Medicinal Products (HMPC)	6 May 2010

<b>Keywords</b>	Herbal medicinal products; HMPC; Community herbal monographs; traditional use; <i>Ribes nigrum</i> L., folium; <i>Ribes nigri folium</i> ; blackcurrant leaf
-----------------	--

BG (bългарски): лист от черно френско грозде CS (čeština): list rybízu černého DA (dansk): DE (Deutsch): Schwarze Johannisbeerblätter EL (ελληνικά): EN (English): blackcurrant leaf ES (español): ET (eesti keel): FI (suomi): FR (français): cassis (feuille de) HU (magyar): IT (italiano):	LT (lietuvių kalba): juodųjų serbentų lapai LV (latviešu valoda): upeņu lapas MT (malti): weraq tar-ribes NL (nederlands): zwarte bes PL (polski): liść porzeczki czarnej PT (português): groselheira-negra, folha RO (română): frunza de coacaz negru SK (slovenčina): list ríbezle čiernej SL (slovenščina): SV (svenska): svartvinbärsblad IS (íslenska): NO (norsk):
---	---



# Community herbal monograph on *Ribes nigrum* L., folium

## 1. Name of the medicinal product

To be specified for the individual finished product.

## 2. Qualitative and quantitative composition<sup>1</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended  i) Herbal substance <i>Ribes nigrum</i> L. folium (blackcurrant leaf)  ii) Herbal preparations  a) Comminuted herbal substance. b) Dry extract (DER 7:1), extraction solvent water

## 3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use. Herbal preparations in solid dosage forms.  The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

## 4. Clinical particulars

### 4.1. Therapeutic indications

Well-established use	Traditional use
	<b>Indication 1)</b> Traditional herbal medicinal product for relief of minor articular pain.  <b>Indication 2)</b> Traditional herbal medicinal product to increase the amount of urine to achieve flushing of the

<sup>1</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Well-established use	Traditional use
	<p>urinary tract as an adjuvant in minor urinary complaints.</p> <p>The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.</p>

#### 4.2. Posology and method of administration

Well-established use	Traditional use
	<p><b>Posology</b></p> <p>Adults, Elderly</p> <p><b>Indication 1)</b> Comminuted herbal substance for infusion as herbal tea preparation: 2 to 4 g per cup 3 times daily.</p> <p><b>Indication 1) and 2)</b> Dry extract (7:1, water) 169 mg 1 to 3 times daily.</p> <p>The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').</p> <p><b>Duration of use</b></p> <p>The herbal substance is traditionally used over a period of 2 (indication 2) to 4 weeks (indication 1).</p> <p>If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p><b>Method of administration</b></p> <p>Oral use.</p> <p>To ensure an increase of the amount of urine, adequate fluid intake is required during treatment.</p>

#### 4.3. Contraindications

Well-established use	Traditional use
	<p>Hypersensitivity to the active substance.</p> <p>Condition was a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).</p>

#### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	<p>The use in children and adolescents under 18 years of age is not recommended.</p> <p>If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p>If complaints of symptoms such as fever, dysuria, spasms or blood in the urine occur during the use of the medicinal product, a doctor or a qualified health care professional should be consulted.</p> <p>Concomitant treatment with synthetic diuretics is not recommended.</p> <p>Articular pain accompanied by swelling of joints, redness or fever, should be examined by a doctor.</p>

#### 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

#### 4.6. Pregnancy and lactation

Well-established use	Traditional use
	<p>Safety during pregnancy and lactation has not been established.</p> <p>In the absence of sufficient data, the use during pregnancy and lactation is not recommended.</p>

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	<p>None known.</p> <p>If adverse reactions occur, a doctor or a</p>

Well-established use	Traditional use
	pharmacist should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

## 5. Pharmacological properties

### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.

### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c (1)(a)(iii) of Directive 2001/83/EC as amended.

### 5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.  Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

## 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

## 7. Date of compilation/last revision

6 May 2010